S
AVXL icon

SignatureFD’s Anavex Life Sciences AVXL Stock Holding History

SignatureFD’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-871
Closed -$2.67K – 3522
2026
Q1 		$2.67K Sell
871
-168
-16% -$728 ﹤0.01% 2978
2025
Q4 		$3.7K Sell
1,039
-190
-15% -$1.16K ﹤0.01% 2797
2025
Q3 		$10.9K Sell
1,229
-104
-8% -$1.05K ﹤0.01% 2377
2025
Q2 		$12.3K Buy
1,333
+431
+48% +$3.68K ﹤0.01% 2268
2025
Q1 		$7.74K Hold
902
– – ﹤0.01% 2452
2024
Q4 		$9.69K Sell
902
-148
-14% -$1.14K ﹤0.01% 2378
2024
Q3 		$5.96K Buy
1,050
+867
+474% +$5K ﹤0.01% 2519
2024
Q2 		$772 Sell
183
-99
-35% -$400 ﹤0.01% 2937
2024
Q1 		$1.44K Sell
282
-187
-40% -$1.05K ﹤0.01% 2885
2023
Q4 		$4.37K Buy
+469
New +$3.23K ﹤0.01% 2539
2022
Q3 		– Sell
-15
Closed – – 3109
2022
Q2 		$0 Buy
15
+5
+50% +$47 ﹤0.01% 3106
2022
Q1 		$0 Hold
10
– – ﹤0.01% 3137
2021
Q4 		$0 Buy
+10
New +$190 ﹤0.01% 3106

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SignatureFD's AVXL Position: Q2 2026 in Review

SignatureFD sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 871 shares — an estimated $2.67K sold.

SignatureFD first reported a position in AVXL in Q4 2021 and held it in 13 quarters. The position peaked at $12.3K in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • SignatureFD reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • SignatureFD sold 871 Anavex Life Sciences shares in Q2 2026, an estimated $2.67K.
  • SignatureFD first reported a position in Anavex Life Sciences in Q4 2021 and held it in 13 quarters.
  • SignatureFD's Anavex Life Sciences position peaked at $12.3K in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.